SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (1936)6/10/1999 4:24:00 PM
From: Don Dorsey  Respond to of 2135
 
Entremed Registers 1M Common Shares For Selling Holders (ENMD)
(NewsTraders.com)-- Entremed Inc. (ENMD) is registering nearly 1 million shares of common stock on behalf of selling holders, according to a Form S-3 filed today with the SEC.
Of the shares being registered, 366,667 are beneficially owned by John W. Holaday, the company's chairman, president and CEO.

Holaday currently holds 1,316,400 shares of Entremed stock, the filing states, and would continue to hold 949,733 shares if all shares being registered are sold.

The registration statement, when cleared by the SEC, lets the holders sell shares of Entremed to the public but doesn't require the holders to divest any stock.

Shares of Entremed, a Rockville, Md., biopharmaceutical company, were recently trading at $25.69, down $0.50 for the day.

Copyright 1999 NewsTraders Inc. All Rights Reserved 16:01 Tuesday, June 08, 1999





To: Biomaven who wrote (1936)6/11/1999 8:46:00 AM
From: John Bloxom  Read Replies (1) | Respond to of 2135
 
Hi Peter:

Are you familiar with OXGN? I'd say that the pre-clinical results on Combretastatin are much more impressive than the results with ango and endo. And, it is an easily synthesized, small molecule drug instead of a hulking, recombinantly produced organic. Might want to check it out.

Regards,

John